Patient Gateway

RSS Feed

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Harpreet Singh: A New Benchmark for KRAS G12C Targeted Therapy in NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC